Table 7.
Multivariate cox regression analysis for the patients with metastatic nasopharyngeal carcinoma
| Characteristic | All patients (n=113) | |||||
|---|---|---|---|---|---|---|
| mOS | mPFS | |||||
| HR | 95%CI | P | HR | 95%CI | P | |
| Gender | ||||||
| Males | 1.517 | 0.887-2.594 | 0.128 | 1.448 | 0.896-2.340 | 0.131 |
| Females | ||||||
| Age (years) | ||||||
| ≤50 | 0.879 | 0.478-1.616 | 0.678 | 1.072 | 0.624-1.840 | 0.802 |
| >50 | ||||||
| Time to disease progress | ||||||
| ≤1 year | 0.372 | 0.214-0.646 | 0.000 | 0.307 | 0.185-0.511 | 0.000 |
| >1 year | ||||||
| ECOG score | ||||||
| 0 | 0.262 | 0.074-0.921 | 0.037 | 0.602 | 0.200-1.813 | 0.367 |
| 1 | ||||||
| Organ involvement | ||||||
| Single | 2.478 | 1.095-5.609 | 0.029 | 2.632 | 1.315-5.267 | 0.006 |
| Multiple | ||||||
| Lung metastasis | ||||||
| Yes | 1.309 | 0.787-2.178 | 0.299 | 1.736 | 1.073-2.809 | 0.025 |
| No | ||||||
| Liver metastasis | ||||||
| Yes | 3.449 | 1.715-6.934 | 0.001 | 1.891 | 1.122-3.185 | 0.017 |
| No | ||||||
| Grouping | ||||||
| Gemcitabine + platinum | 2.650 | 1.469-4.783 | 0.001 | 1.768 | 1.052-2.973 | 0.032 |
| Docetaxel + platinum | ||||||
mPFS – Median progression-free survival; mOS – Median overall survival; CI – Confidence interval; HR – Hazards ratio; ECOG – Eastern cooperative oncology group